Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6312122 | 0.78 | — | — | |
| SCHEMBL6306589 | 0.77 | DHFR (0.57) | DHFR | |
| SCHEMBL6390075 | 0.75 | DHFR (0.44) | DHFREGFRKDR | |
| SCHEMBL5476985 | 0.71 | DHFR (0.49) | DHFRKDR | |
| SCHEMBL5476982 | 0.71 | DHFR (0.49) | DHFRKDR | |
| SCHEMBL4871146 | 0.70 | DHFR (0.47) | DHFREGFRKDR | |
| SCHEMBL13833594 | 0.70 | DHFR (0.47) | DHFREGFRKDR | |
| SCHEMBL2915133 | 0.69 | DHFR (0.46) | DHFREGFRKDR | |
| SCHEMBL13833595 | 0.69 | DHFR (0.46) | DHFREGFRKDR | |
| SCHEMBL6310645 | 0.69 | DHFR (0.47) | DHFREGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962920-B2 | Pyrimidine derivatives and methods of making and using these derivatives | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2004-02-26 | — | — | US | disclosed |
| US-6537999-B2 | Furopyrimidines and pyrrolopyrimidines; treating cancer, and secondary infections caused by Pneumocystis carinii and Toxoplasmosis gondii in immunocompromised patients. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2003-03-25 | — | — | US | disclosed |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | GANGJEE ALEEM (US) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039000-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | DHFR 11/4885EGFR 4760/4885KDR 4310/4885 |
| US-20020052384-A1 | Novel pyrimidine derivatives and methods of making and using these derivatives | TYMP, TYMS, DPYD | DHFR 11/4885EGFR 4760/4885KDR 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.